Skip to main content
    L

    Lexaria Bioscience Corp (LEXX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.11
    -0.33 (-7.43%)

    Market Cap: $9.35M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Lexaria Bioscience Corp (LEXX) Financials: Revenue, Profit and Cash Flow

    Updated Jul 13, 2026. Financial statements from company filings, amounts in US dollars.

    Lexaria Bioscience reported revenue of $705.92K for the fiscal year ended Aug 31, 2025, up 52.0% from the year before. That year, net income was -$11.90M with a net margin of -1686.0%, operating cash flow was -$10.45M and free cash flow was -$10.48M. The quarter ended May 31, 2026 had revenue of $0 and net income of -$1.99M.

    Revenue and Margins

    Over the 9 years to Aug 2025, revenue grew from $40.72K, a compound annual rate of 37.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Aug 2025$705.92K+52.0%99.6%-1683.0%-1686.0%
    Aug 2024$464.28K+105.2%99.0%-1239.2%-1248.2%
    Aug 2023$226.21K-11.4%86.1%-2888.5%-2946.4%
    Aug 2022$255.40K-64.7%71.9%-2591.7%-2846.3%
    Aug 2021$722.74K+87.9%75.7%-786.8%-557.2%
    Aug 2020$384.54K+72.7%56.0%-1078.9%-1023.0%
    Aug 2019$222.61K-48.6%89.7%-1823.7%-1841.5%
    Aug 2018$433.29K+580.9%94.2%-1523.3%-1523.0%
    Aug 2017$63.64K+56.3%53.3%-2914.6%-2937.3%
    Aug 2016$40.72KN/A-12.0%-3023.1%-2983.4%
    Annual, fiscal years ended Aug 2016 to Aug 2025

    Income Statement

    In the fiscal year ended Aug 2025, the net loss widened from the year before. In the quarter ended May 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemAug 2025Aug 2024Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016
    Revenue$705.92K$464.28K$226.21K$255.40K$722.74K$384.54K$222.61K$433.29K$63.64K$40.72K
    Cost of revenue$2.72K$4.82K$31.50K$71.84K$175.35K$99.38K$22.89K$25.18K$29.75K$45.62K
    Gross profit$703.20K$459.46K$194.71K$183.56K$547.39K$215.41K$199.72K$408.10K$33.89K-$4.90K
    Research and development$8.24M$2.36M$3.67M$1.84M$1.26M$387.07K$555.73K$492.86K$54.19K$9.02K
    Operating income-$11.88M-$5.75M-$6.53M-$6.62M-$5.69M-$4.15M-$4.06M-$6.60M-$1.85M-$1.23M
    Net income-$11.90M-$5.80M-$6.66M-$7.27M-$4.03M-$3.93M-$4.10M-$6.60M-$1.87M-$1.21M
    EBITDA-$11.82M-$5.73MN/AN/A-$4.02M-$4.00M-$4.00M-$6.60MN/AN/A
    Fiscal years ended Aug 2016 to Aug 2025

    Quarterly

    Line itemMay 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023
    Revenue$0$20.00K$0$174.00K$174.00K$174.00K$183.92K$84.00K$84.00K$145.00K$151.28K-$3.43K
    Gross profit$0$20.00K-$24.20K$174.00K$174.00K$174.00K$181.20K$84.00K$84.00K$145.00K$146.46K-$3.43K
    Operating income-$1.99M-$1.45M-$1.57M-$2.69M-$3.75M-$2.75M-$2.69M-$2.20M-$1.74M-$668.00K-$1.14M-$1.07M
    Net income-$1.99M-$1.45M-$1.60M-$2.70M-$3.79M-$2.71M-$2.70M-$2.18M-$1.78M-$649.54K-$1.18M-$1.24M
    Last 12 quarters

    Balance Sheet

    As of Aug 2025, cash and equivalents exceeded short-term debt of $30.42K by $1.77M.

    Annual

    Line itemAug 2025Aug 2024Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016
    Total assets$4.18M$8.87M$3.08M$7.83M$13.27M$2.83M$2.68M$2.43M$2.86M$566.64K
    Current assets$3.47M$7.90M$2.20M$6.98M$12.44M$1.93M$1.82M$2.28M$2.80M$510.17K
    Cash and equivalents$1.80M$6.50M$1.35M$5.81M$10.92M$1.29M$1.29M$1.73M$2.53M$93.41K
    Total liabilities$1.57M$1.21M$403.91K$201.44K$203.26K$345.98K$184.51K$43.64K$92.35K$478.88K
    Short-term debt$30.42K$28.05K$27.79K$42.59K$47.33K$36.04KN/AN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$30.67KN/AN/AN/AN/A
    Shareholder equity$2.99M$8.04M$3.04M$7.95M$13.27M$2.53M$2.38M$2.39M$3.01M$266.05K
    Fiscal years ended Aug 2016 to Aug 2025

    Quarterly

    Line itemMay 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023
    Total assets$4.78M$6.49M$6.05M$4.18M$6.74M$8.68M$9.79M$8.87M$10.02M$6.35M$3.63M$3.08M
    Total liabilities$437.09K$277.00K$1.53M$1.57M$1.57M$1.92M$399.72K$1.21M$271.38K$204.20K$254.04K$403.91K
    Cash and equivalents$3.48M$5.13M$4.28M$1.80M$4.59M$6.47M$8.08M$6.50M$8.46M$4.71M$1.95M$1.35M
    Shareholder equity$4.74M$6.60M$4.91M$2.99M$5.55M$7.14M$9.77M$8.04M$10.12M$6.52M$3.74M$3.04M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Aug 2025.

    Annual

    Line itemAug 2025Aug 2024Aug 2023Aug 2022Aug 2021Aug 2020Aug 2019Aug 2018Aug 2017Aug 2016
    Operating cash flow-$10.45M-$4.96M-$5.88M-$4.88M-$3.99M-$2.62M-$3.01M-$2.52M-$1.55M-$660.86K
    Capital expenditures$24.64K$43.02K$169.61K$49.19K$79.49K$33.65K$769.16K$85.40K$9.70K$20.10K
    Free cash flow-$10.48M-$5.00M-$6.05M-$4.93M-$4.07M-$2.65M-$3.77M-$2.60M-$1.56M-$680.96K
    Investing cash flow-$243.02K-$188.60K-$169.61K-$180.64K$193.88K-$26.84K-$769.16K-$155.40K-$9.70K-$20.10K
    Financing cash flow$6.05M$10.32M$1.59M-$44.60K$13.42M$2.65M$3.33M$1.87M$4.00M$514.29K
    Fiscal years ended Aug 2016 to Aug 2025

    Quarterly

    Line itemMay 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023
    Operating cash flow-$1.64M-$2.16M-$984.10K-$2.64M-$3.58M-$1.50M-$2.73M-$1.89M-$1.27M-$619.61K-$1.18M-$1.62M
    Capital expenditures$26.25K$55.91K$5.10K$14.61K$19.44K$27.89K$37.80K$69.59K$22.00K$56.99K$40.03K$68.44K
    Free cash flow-$1.66M-$2.22M-$989.20K-$2.66M-$3.60M-$1.53M-$2.76M-$1.96M-$1.29M-$676.60K-$1.22M-$1.69M
    Last 12 quarters

    Frequently Asked Questions About LEXX

    What is Lexaria Bioscience's annual revenue?

    Lexaria Bioscience reported revenue of $705.92K for the fiscal year ended Aug 31, 2025.

    How fast is Lexaria Bioscience's revenue growing?

    Revenue was up 52.0% for the fiscal year ended Aug 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.3%.

    Is Lexaria Bioscience profitable?

    No. Lexaria Bioscience reported net income of -$11.90M for the fiscal year ended Aug 31, 2025, with a net margin of -1686.0%.

    How much free cash flow does LEXX generate?

    For the fiscal year ended Aug 31, 2025, operating cash flow of -$10.45M minus capital expenditures of $24.64K produced free cash flow of -$10.48M.

    How much debt does Lexaria Bioscience have?

    The balance sheet dated Aug 31, 2025 reported short-term debt of $30.42K and cash and equivalents of $1.80M.